[CH:1](=[N:3][OH:4])[CH3:2].ClN1C(=O)CCC1=O.[C:13]([C:16]1[CH:21]=[CH:20][C:19]([CH2:22][C:23]([NH:25][C@@H:26]([C:28]2[CH:33]=[CH:32][C:31]([O:34][CH2:35][C:36]([F:39])([F:38])[F:37])=[CH:30][N:29]=2)[CH3:27])=[O:24])=[CH:18][CH:17]=1)([CH3:15])=[CH2:14]>>[CH3:2][C:1]1[CH2:15][C:13]([C:16]2[CH:17]=[CH:18][C:19]([CH2:22][C:23]([NH:25][C@@H:26]([C:28]3[CH:33]=[CH:32][C:31]([O:34][CH2:35][C:36]([F:39])([F:37])[F:38])=[CH:30][N:29]=3)[CH3:27])=[O:24])=[CH:20][CH:21]=2)([CH3:14])[O:4][N:3]=1To a solution of acetaldoxime (14.1 mg, 0.238 mmol) was added N-chlorosuccinimide (31.8 mg, 0.238 mmol). The resulting mixture was stirred at room temperature for 3 h. 2-(4-Isopropenylphenyl)-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide (90 mg, 0.24 mmol) was added, followed by the TEA (0.099 ml, 0.71 mmol), the resulting mixture was stirred at room temperature for 24 h. The reaction mixture was washed with saturated sodium bicarbonate solution and brine. Organics were extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated in vacuo. Purification by reverse phase chromatography gave 2-[4-(3,5-dimethyl-4,5-dihydro-isoxazol-5-yl)phenyl]-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide as a white solid (23.8 mg, 23%). 1H NMR (CDCl3, 400 MHz). δ 8.299 (dd, J=2.75, 5.31 Hz, 1H); 7.407 (t, J=2.93 Hz, 1H); 7.361 (dd, J=1.28 Hz, J=8.42 Hz, 4H); 7.243 (d, J=2.20 Hz, 1H); 7.222 (d, J=2.38 Hz, 1H); 5.122 (quintet, J=7.14 Hz, 1H); 4.436 (m, 2H); 3.550 (s, 2H); 3.063 (m, 2H); 1.965 (t, J=1.10 Hz, 3H); 1.684 (d, J=1.10 Hz, 2H); 1.466 (d, J=6.96 Hz, 3H); MS (ES): m/z 436.2 (M+H). FLIPR alpha1I IP=41 nM.